小血管,大问题:深入研究肺高血压中的肺微循环,以及评估方法
Misha Dagan1, Shane Nanayakkara2, William Chan3
1Department of Cardiology, Alfred Hospital, Melbourne, Australia; Monash University, Faculty of Medicine, Nursing and Health Sciences, Clayton, Melbourne, Australia.
EBioMedicine
|July 27, 2025
概括
在肺高血压 (PH) 中评估肺微血管功能障碍是关键. 新的成像,建模和侵入性方法为早期诊断和量身定制的治疗提供了更好的评估.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 医疗成像医学成像
- 计算生物学 计算生物学
背景情况:
- 肺微血管功能障碍是肺高血压 (PH) 病理生理学的核心问题.
- 在PH患者肺微循环的临床评估仍然很困难.
研究的目的:
- 审查目前和新兴的评估肺微循环的方法.
- 探索这些方法如何改善PH诊断,表型和治疗.
主要方法:
- 复习先进的成像技术.
- 对计算建模方法的分析.
- 检查侵入性血液动力学评估 (例如,运动右心脏导管,肺流储备).
主要成果:
- 像血管活性测试这样的现有方法提供了间接的见解.
- 新型的侵入性技术和计算模型对精确的表征和早期检测有希望.
- 许多工具目前正在研究中,但具有临床整合的潜力.
结论:
- 精细和综合的评估工具可以导致更早的PH诊断和个性化的风险分层.
- 这些进展可能使微血管功能障碍的向治疗成为可能.
- 这些创新方法的临床转化对于改善患者的治疗结果至关重要.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
291
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
291
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
319
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
319
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
259
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
259
Pulmonary Embolism I: Introduction
46
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
46
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.6K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.6K


